Astellas, Gilead Sue Pharma Supplier Curia Over Lexiscan Patent

Gilead Sciences Inc. and two of Astellas Pharma Inc.’s U.S. subsidiaries filed a patent-infringement lawsuit alleging that Curia Global Inc. and its Missouri unit, suppliers of the active pharmaceutical ingredient in Astellas’ Lexiscan, infringe a patent for the injectable drug, used to help doctors detect coronary artery disease.

The companies filed the complaint under seal late Monday “to protect alleged confidential commercial information belonging to” Curia and related to its manufacture and sales of regadenoson, Lexiscan’s active ingredient, according to court papers filed concurrently in the U.S. District Court for the District of Delaware.

The patent at issue, owned by ...